-
Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin.
Cell. 2014 Aug 14;158(4):929-944
PMID: 25109877
-
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
J Clin Oncol. 2007 May 20;25(15):2127-32
PMID: 17513820
-
When progressive disease does not mean treatment failure: reconsidering the criteria for progression.
J Natl Cancer Inst. 2012 Oct 17;104(20):1534-41
PMID: 22927506
-
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Cancer Cell. 2010 Jan 19;17(1):98-110
PMID: 20129251
-
Challenges of guarantee-time bias.
J Clin Oncol. 2013 Aug 10;31(23):2963-9
PMID: 23835712
-
Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas.
JAMA Oncol. 2017 Dec 1;3(12):1654-1662
PMID: 28472234
-
Crossover effects of estrogen receptor status on breast cancer-specific hazard rates by age and race.
PLoS One. 2014 Oct 21;9(10):e110281
PMID: 25333877
-
Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.
Stat Med. 1996 Feb 28;15(4):361-87
PMID: 8668867
-
Genomic Classification of Cutaneous Melanoma.
Cell. 2015 Jun 18;161(7):1681-96
PMID: 26091043
-
End points and United States Food and Drug Administration approval of oncology drugs.
J Clin Oncol. 2003 Apr 1;21(7):1404-11
PMID: 12663734
-
Survival analysis part I: basic concepts and first analyses.
Br J Cancer. 2003 Jul 21;89(2):232-8
PMID: 12865907
-
Comprehensive genomic characterization of squamous cell lung cancers.
Nature. 2012 Sep 27;489(7417):519-25
PMID: 22960745
-
Analysis of survival by tumor response and other comparisons of time-to-event by outcome variables.
J Clin Oncol. 2008 Aug 20;26(24):3913-5
PMID: 18711176
-
Minimum follow-up time required for the estimation of statistical cure of cancer patients: verification using data from 42 cancer sites in the SEER database.
BMC Cancer. 2005 May 17;5:48
PMID: 15904508
-
Integrated genomic analyses of ovarian carcinoma.
Nature. 2011 Jun 29;474(7353):609-15
PMID: 21720365
-
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials.
BMC Med. 2010 Mar 24;8:18
PMID: 20334633
-
Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy.
J Clin Endocrinol Metab. 2012 Dec;97(12):E2201-9
PMID: 22993034
-
Analysis of survival by tumor response.
J Clin Oncol. 1983 Nov;1(11):710-9
PMID: 6668489
-
Comprehensive molecular portraits of human breast tumours.
Nature. 2012 Oct 4;490(7418):61-70
PMID: 23000897
-
Molecular portraits of human breast tumours.
Nature. 2000 Aug 17;406(6797):747-52
PMID: 10963602
-
Integrated genomic and molecular characterization of cervical cancer.
Nature. 2017 Mar 16;543(7645):378-384
PMID: 28112728
-
Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study.
J Clin Oncol. 2011 Nov 1;29(31):4199-204
PMID: 21969501
-
Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates.
J Clin Epidemiol. 1995 Dec;48(12):1503-10
PMID: 8543964
-
Comprehensive molecular characterization of urothelial bladder carcinoma.
Nature. 2014 Mar 20;507(7492):315-22
PMID: 24476821
-
Risk factors for local recurrence in patients with invasive breast cancer and negative surgical margins of excision. Where are we and where are we going?
Am J Clin Pathol. 2003 Oct;120(4):485-8
PMID: 14560560
-
REporting recommendations for tumour MARKer prognostic studies (REMARK).
Br J Cancer. 2005 Aug 22;93(4):387-91
PMID: 16106245
-
Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence.
J Clin Oncol. 2015 Nov 1;33(31):3621-7
PMID: 26371147
-
The Molecular Taxonomy of Primary Prostate Cancer.
Cell. 2015 Nov 5;163(4):1011-25
PMID: 26544944
-
Comprehensive genomic characterization defines human glioblastoma genes and core pathways.
Nature. 2008 Oct 23;455(7216):1061-8
PMID: 18772890
-
The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.
CA Cancer J Clin. 2017 Mar;67(2):93-99
PMID: 28094848
-
Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.
J Clin Oncol. 2015 Mar 20;33(9):1008-14
PMID: 25667291
-
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.
PLoS Med. 2012;9(5):e1001216
PMID: 22675273
-
Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials.
Int J Clin Oncol. 2009 Apr;14(2):102-11
PMID: 19390940
-
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
Acta Neuropathol. 2016 Jun;131(6):803-20
PMID: 27157931
-
Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival--A study from the groupe d'etude des lymphomes de l'adulte.
J Clin Oncol. 2010 Feb 10;28(5):822-9
PMID: 20026809
-
Integrated genomic characterization of endometrial carcinoma.
Nature. 2013 May 2;497(7447):67-73
PMID: 23636398
-
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
N Engl J Med. 2015 Jun 25;372(26):2481-98
PMID: 26061751
-
Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials.
J Natl Cancer Inst. 2007 Jul 4;99(13):998-1003
PMID: 17596575
-
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
N Engl J Med. 2005 Mar 10;352(10):987-96
PMID: 15758009
-
Annual hazard rates of recurrence for breast cancer after primary therapy.
J Clin Oncol. 1996 Oct;14(10):2738-46
PMID: 8874335
-
A simulation study of the number of events per variable in logistic regression analysis.
J Clin Epidemiol. 1996 Dec;49(12):1373-9
PMID: 8970487